Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody (ab110474)

Overview

  • Product nameAnti-Pyruvate Dehydrogenase E1-alpha subunit antibody
    See all Pyruvate Dehydrogenase E1-alpha subunit primary antibodies
  • Description
    Rabbit polyclonal to Pyruvate Dehydrogenase E1-alpha subunit
  • Specificityab110474 detects endogenous levels of total Pyruvate Dehydrogenase E1-alpha subunit protein.
  • Tested applicationsSuitable for: WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide derived from an internal region of Human Pyruvate Dehydrogenase E1-alpha subunit (UniProt ID: P08559).

  • Positive control
    • WB: Extracts from A549, HepG2 and Jurkat cells IHC-P: Human breast carcinoma tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab110474 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 43 kDa.
IHC-P 1/50 - 1/100. Antigen retrieval is heat-mediated, citrate buffer pH 6.0. A pressure cooker was used for about 5 minutes.

Target

  • FunctionThe pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3).
  • Tissue specificityUbiquitous.
  • Involvement in diseaseDefects in PDHA1 are a cause of pyruvate decarboxylase E1 component deficiency (PDHE1 deficiency) [MIM:312170]. PDHE1 deficiency is the most common enzyme defect in patients with primary lactic acidosis. It is associated with variable clinical phenotypes ranging from neonatal death to prolonged survival complicated by developmental delay, seizures, ataxia, apnea, and in some cases to an X-linked form of Leigh syndrome (X-LS).
    Defects in PDHA1 are the cause of X-linked Leigh syndrome (X-LS) [MIM:308930]. X-LS is an early-onset progressive neurodegenerative disorder with a characteristic neuropathology consisting of focal, bilateral lesions in one or more areas of the central nervous system, including the brainstem, thalamus, basal ganglia, cerebellum, and spinal cord. The lesions are areas of demyelination, gliosis, necrosis, spongiosis, or capillary proliferation. Clinical symptoms depend on which areas of the central nervous system are involved. The most common underlying cause is a defect in oxidative phosphorylation. LS may be a feature of a deficiency of any of the mitochondrial respiratory chain complexes.
  • Cellular localizationMitochondrion matrix.
  • Information by UniProt
  • Database links
  • Alternative names
    • ODPA_HUMAN antibody
    • PDH antibody
    • PDHA antibody
    • PDHA1 antibody
    • PDHCE1A antibody
    • PDHE1 A type I antibody
    • PDHE1-A type I antibody
    • PHE1A antibody
    • Pyruvate Dehydrogenase (lipoamide) alpha 1 antibody
    • Pyruvate dehydrogenase complex, E1 alpha polypeptide 1 antibody
    • Pyruvate Dehydrogenase E1 alpha antibody
    • Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial antibody
    see all

Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody images

  • All lanes : Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody (ab110474) at 1/500 dilution

    Lane 1 : Extracts from Jurkat cells
    Lane 2 : Extracts from HepG2 cells
    Lane 3 : Extracts from A549 cells
    Lane 4 : Extracts from Jurkat cells, treated with the synthesized peptide

    Lysates/proteins at 30 µg per lane.


    Predicted band size : 43 kDa
  • ab110474, at a 1/50 dilution, staining Pyruvate Dehydrogenase E1-alpha subunit in paraffin embedded Human breast carcinoma tissue by Immunohistochemistry, in the absence (left image) or presence (right image) of the synthesized peptide.

References for Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody (ab110474)

ab110474 has not yet been referenced specifically in any publications.

Product Wall

Yes, ab110474 was run under reduced, denatured conditions.

Application Immunohistochemistry (Frozen sections)
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Sample Mouse Tissue sections (mouse brain tissue sections)
Specification mouse brain tissue sections
Permeabilization Yes - 0.3% of triton-X 100
Fixative Paraformaldehyde
Username

Qian Ma

Verified customer

Submitted Jan 03 2014

I am very pleased to hear you would like to accept our offer and test ab110474 in mouse. This code will give you $337 off your next order before the expiration date. To redeem this offer, please submit an Abreview for mouse and include this code in the...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"